How to treat atherosclerosis? - Highlights of the EAS 2024 (Part I)

Professor Philippe Moulin shares his insights on the highlights of the EAS 2024 and how to treat atherosclerosis. The first part of our two-part interview covered the following topics: -    Combating the triple threat: Cardiovascular disease, Diabetes mellitus, Chronic kidney disease. -    Real world solutions for LDL-C management. -    Can therapies alter the course of atherosclerotic cardiovascular disease?  Shall we treat inflammation in atherosclerosis? -    Role of diet and lifestyle in prevention and treatment of atherosclerosis? To watch the second part of the interview, click on the link below: https://medicaldigest.org/scientific-contents/interview:how-treat-atherosclerosis-highlights-eas-2024-part-ii

How to treat atherosclerosis? - Highlights of the EAS 2024 (Part II)

Professor Philippe Moulin shares his insights on the highlights of the EAS 2024 and how to treat atherosclerosis. The second part of our two-part interview  -    New insights in the genetics of dyslipidaemia -    New data from the registries: INTERSPIRE -    Anitschkow Prize & Lecture 2024: Recipient: Bart Staels -    ESC/EAS Joint Symposium on risk scores, modifiers and comorbidities To watch the first part of the interview, click here:  https://medicaldigest.org/scientific-contents/interview:how-treat-atherosclerosis-highlights-eas-2024-part-i

Overview of the 2024 EAS Congress

We asked Professor Kausik Ray, President of the European Atherosclerosis Society about 2024 EAS Congress and the Society, as well as the Joint Sessions and the Anitschkow Lecture.

Controlling the uncontrollable - resistant hypertension and the role of aldosterone

Professor Michel Azizi on aldosterone receptor blocker versus aldosterone synthase inhibitor. Who is more effective in blocking aldosterone?

Management of older hypertensive patients

Professor Athanase Benetos on how to take care and treat hypertensive older people.

ESH guidelines 2023: a new light on beta-blockers in hypertension

Professor Giuseppe Mancia on the update of ESH guidelines 2023.

ESH - ESC HFA Joint meeting: HFpEF update 2024

Professor Enrico Agabiti Rosei on heart failure with preserved ejection fraction updates at ESH 2024.

2023 ESH Hypertension Guideline Update

Combination of a beta-blocker with calcium channel blocker in hypertension

Professor Gianfranco Parati share his thoughts on combination of a beta-blocker with calcium channel blocker in hypertension.

ESH Clinical Practice Guidelines

Professor Roland Schmieder, Co-Chair of ESH 2024 on the ESH 2024 Congress and the updated Guidelines.

Nephroprotection using SGLT2 inhibitors in patients with hypertension

Professor Michael Böhm on evolving standard of care and SGLT2 inhibitors for patients with CKD and hypertension.

Diabetes and Metabolic risk factors

Professor Josep Redon chaired an interesting session on Diabetes and Metabolic risk factors at ESH 2024.

Beta-blockers in hypertension and CVD

Professor Ricardo Fontes-Carvalho on the role of beta-blockers in the treatment of hypertension and cardiologic diseases.

ESH - ISH Joint Session: Balancing common side effects of Thiazide/Thiazide-like diuretics through addition of other Blood Pressure lowering drugs

Professor Jorie Versmissen and Professor Fadi Charchar discussed the ESH - ISH Joint Session on balancing common side effects of Thiazide/Thiazide-like diuretics through addition of other Blood Pressure lowering drugs.

How lifestyle affects hypertension

Professor Fadi Charchar on how lifestyle affects hypertension and what a patient could do to prevent hypertension and reduce then blood pressure.

Overcoming the resistance - Is renal denervation the solution?

Professor Konstantinos Tsioufis shares his thoughts on the novelties of kidney protection in hypertension.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention